Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

BACKGROUND: This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. METHODS: A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, B Douglas, Beach, Charles L, Mahmoud, Dalia, Weber, Laura, Henk, Henry J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994315/
https://www.ncbi.nlm.nih.gov/pubmed/24666795
http://dx.doi.org/10.1186/2162-3619-3-10
_version_ 1782312709299109888
author Smith, B Douglas
Beach, Charles L
Mahmoud, Dalia
Weber, Laura
Henk, Henry J
author_facet Smith, B Douglas
Beach, Charles L
Mahmoud, Dalia
Weber, Laura
Henk, Henry J
author_sort Smith, B Douglas
collection PubMed
description BACKGROUND: This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. METHODS: A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012. RESULTS: Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007) and a lower risk of hospitalization (HR 0.787, p = 0.02) compared to treatment with decitabine. CONCLUSIONS: This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests that azacitidine may result in clinically superior outcomes than decitabine.
format Online
Article
Text
id pubmed-3994315
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39943152014-04-23 Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis Smith, B Douglas Beach, Charles L Mahmoud, Dalia Weber, Laura Henk, Henry J Exp Hematol Oncol Research BACKGROUND: This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. METHODS: A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012. RESULTS: Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007) and a lower risk of hospitalization (HR 0.787, p = 0.02) compared to treatment with decitabine. CONCLUSIONS: This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests that azacitidine may result in clinically superior outcomes than decitabine. BioMed Central 2014-03-25 /pmc/articles/PMC3994315/ /pubmed/24666795 http://dx.doi.org/10.1186/2162-3619-3-10 Text en Copyright © 2014 Smith et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Smith, B Douglas
Beach, Charles L
Mahmoud, Dalia
Weber, Laura
Henk, Henry J
Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
title Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
title_full Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
title_fullStr Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
title_full_unstemmed Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
title_short Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
title_sort survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994315/
https://www.ncbi.nlm.nih.gov/pubmed/24666795
http://dx.doi.org/10.1186/2162-3619-3-10
work_keys_str_mv AT smithbdouglas survivalandhospitalizationamongpatientswithacutemyeloidleukemiatreatedwithazacitidineordecitabineinalargemanagedcarepopulationarealworldretrospectiveclaimsbasedcomparativeanalysis
AT beachcharlesl survivalandhospitalizationamongpatientswithacutemyeloidleukemiatreatedwithazacitidineordecitabineinalargemanagedcarepopulationarealworldretrospectiveclaimsbasedcomparativeanalysis
AT mahmouddalia survivalandhospitalizationamongpatientswithacutemyeloidleukemiatreatedwithazacitidineordecitabineinalargemanagedcarepopulationarealworldretrospectiveclaimsbasedcomparativeanalysis
AT weberlaura survivalandhospitalizationamongpatientswithacutemyeloidleukemiatreatedwithazacitidineordecitabineinalargemanagedcarepopulationarealworldretrospectiveclaimsbasedcomparativeanalysis
AT henkhenryj survivalandhospitalizationamongpatientswithacutemyeloidleukemiatreatedwithazacitidineordecitabineinalargemanagedcarepopulationarealworldretrospectiveclaimsbasedcomparativeanalysis

Ejemplares similares